Ohr Pharmaceutical, Inc. (OHRP) was a big mover last session with its shares rising over 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend of the company since Feb 11, as the stock has lost almost 9% in the past five trading sessions.
This biotechnology company has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Ohr Pharmaceutical currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked Med-Drug stocks include Endocyte, Inc. (ECYT), Lannett Company, Inc. (LCI) and Ariad Pharmaceuticals Inc. (ARIA). While ECYT and LCI sport a Zacks Rank #1 (Strong Buy), ARIA carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment